Search 

Jean Yao, PhD, with 20+ years of extended experience in the areas of biology, medical research, and medical industry, has held various positions at Mayo Clinic and University of Minnesota. She funded Med Qiao Group LLC as for the Bridge between US and China in life science. Med Qiao provides business consulting services that include investment funding, market analysis, intellectual property protection, clinical trial arrangement, product approval application, China branch or division establishment as well as marketing, promotion, distribution and onsite manufacturing of medical products.

Medtronic was founded in 1949 and is based in Minneapolis Minnesota. Medtronic makes strategic investments and acquisitions in the medical device sector and is focused on cardiovascular diseases diabetes diseases of the nervous system (including Parkinson's disease and dystonia) and musculoskeletal conditions. The firm has acquired a number of medical technology and biotechnology companies. Medtronic is also interested in orthopedic products sports health products and telehealth/connected medical devices (particularly consumer apps for health management). Medtronic also makes grants to non-profit organizations. Instructions on applying for investment or grants can be found at Innovate With Medtronic: http://www.medtronic.com/innovation/innovate-with-medtronic.html

Mesa Verde Venture Partners is a Venture Capital company founded in 2006. The firm is currently making investments out of its 2nd fund that had its first close in 2013. The firm makes primarily equity investment into seed and early stage rounds ranging from $500,000 to $1 million initially and up to $1.5 million over the lifetime of the investment. The firm is focused on companies located in the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

The Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute supports the development of innovative biomedical products to address unmet medical needs in the heart, lung, blood and sleep fields.  OTAC is home to the NHLBI's small business programs (SBIR and STTR) and the NIH Centers for Accelerated Innovations.

The NHLBI's SBIR and STTR programs comprise one of the largest sources of early-stage capital for U.S. small business, acting as engines of innovation for developing and commercializing novel technologies and products that aid in the prevention, diagnosis, and treatment of heart, lung, blood, and sleep diseases and disorders. The NHLBI provides grant and contract funding opportunities and resources to support small businesses performing research and development on technologies related to the mission of NHLBI. With an annual budget of $85M, the NHLBI funds about 200 companies each year through the Institute's small business programs.

The NIH Centers for Accelerated Innovations accelerate translation of scientific discovery into commercial products that improve health for patients. This unique public-private partnership is changing the way discoveries with scientific and commercial potential are identified and developed.

NeuroTronik Limited is a development-stage, venture-backed medical device company pursuing a unique neuromodulation approach to improve cardac output for patients who come to the hospital with Acute Heart Failure Syndrome. With a seasoned team of engineers, advisors, and investors, NeuroTronik is on-track in project milestone achievement. Though a moderately-sized project, the market potential is exceptional.

NeuroTronik is planning a $20 million Series B preferred stock financing in late 2015. Those proceeds are designed to take the therapy through and into commercial sales in Europe.

Our named investors are Hatteras Venture Partners, Synergy Life Science Partners, Mountain Group Capital, and Lord Baltimore Capital.

The CEO is Fred McCoy. The CTO is Steve Masson.

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).